Print
Email
Print Edition StoriesWednesday, June 3, 2009
CombinatoRx notes good results for reworked osteoarthritis drug
By Mass High Tech staff
MHT's Marc Songini: Technology to keep seniors healthy
MHT's Marc Songini: Researchers focus on macular degeneration
MHT's Marc Songini: Mass. bio firms prep for lifting of stem cell ban
CombinatoRx Inc. reported positive Phase 1 clinical study results of Synavive, its knee treatment for osteoarthritis. The drug received poor Phase 2b clinical trial results as a twice-daily formulation; the Phase 1 drug is an oral once-daily aligned-release formulation.
The goal of the clinical study was to determine the drug’s bioavailability, its ability to be absorbed into the body.
According to CombinatoRx (Nasdaq: CRXX) officials, the once-daily drug was “well-tolerated and there were no study drug-related serious adverse events reported.” The company found a 30 percent rate of headaches in patients taking the drug. In the company’s prior twice-daily formulation of Synavive, patients reported a 50 percent headache rate.
CombinatoRx’ Phase 1 study involved 24 volunteers over a period of four weeks.
The company’s poor results of its Phase 2b clinical trials for Synavive was brought about by statistically insignificant results in a knee pain measurement test for patients walking on a flat surface for both the placebo and Synavive.
The results of the Phase 2b clinical trials began a series of downfalls for the company that started with a 73 percent drop in stock, a 45 percent cut in workforce, and follow-up job reductions weeks later.
CombinatoRx reported a net loss of $9.4 million on total revenue of $3 million for the first quarter of 2009, ending in March.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
